Upstream Bio to Participate in Upcoming March Investor Conferences
Upstream Bio: Hold Rating As Verekitug Faces Competition Among Latest Asthma Data [Seeking Alpha]
Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma
Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma [Yahoo! Finance]
Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma